5
total announcements
538965.BO · 15 min delayed
Concord Drugs Ltd
Concord Drugs Ltd has announced the closure of its trading window for the consideration of unaudited financial results for the quarter and year ending September 30, 2026, from October 1, 2026, until 48 hours after the announcement of the results.
Concord Drugs Ltd
Concord Drugs Ltd has published its unaudited financial results for the quarter ended 30th June 2026 in newspapers. The company has also mentioned that it is complying with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the announcement also contains a public notice for the sale of immovable assets of Can Fin Homes Ltd, which is unrelated to Concord Drugs Ltd.
Concord Drugs Ltd
Concord Drugs Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, showing revenue from operations of Rs. 2,088.86 lakhs and a net profit of Rs. 111.23 lakhs. The company's earnings per share (EPS) for the quarter is Rs. 0.84. The financial results are available on the company's website and on the BSE website.
Concord Drugs Ltd
Concord Drugs Ltd announces its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 2,088.86 lakhs and profit before tax at Rs. 154.26 lakhs.
Concord Drugs Ltd
Concord Drugs Ltd has scheduled a board meeting on 10/08/2026 to consider and approve the un-audited financial results for the quarter ended 30/06/2026.